Brief: Mithra Pharmaceuticals Announces Topline Results For COVID-19 Phase II Study

Mithra Pharmaceuticals SA

24/09/2021 06:53

Sept 24 (Reuters) - MITHRA PHARMACEUTICALS SA  MITRA.BR :
    * MITHRA ANNOUNCES TOPLINE RESULTS FOR COVID-19 PHASE II
STUDY
    * ESTETROL (E4) DID NOT DIFFER FROM PLACEBO ON THE PRIMARY
STUDY
ENDPOINT, BUT NO FIRM CONCLUSION CAN BE MADE DUE TO CONFOUNDING
FACTORS
    * E4 WAS WELL-TOLERATED WITH NO APPARENT SAFETY SIGNALS IN
HOSPITALIZED MEN OR POST-MENOPAUSAL WOMEN SUFFERING FROM
MODERATE COVID-19
    * NO ADVERSE EFFECT OBSERVED ON CLOTTING MARKERS OR COVID-19
RELATED EMBOLIC EVENTS
    * OUT OF 175 PATIENTS WHO ENTERED THE STUDY, 171 PATIENTS
WERE
EVALUATED FOR EFFICACY AND ALL PATIENTS WERE EVALUATED FOR
SAFETY
    * THIS IS THE FIRST PROSPECTIVE CLINICAL TRIAL OF AN
ESTROGEN TO
REPORT RESULTS IN COVID-19
    * THERE WERE NO SAFETY OR TOLERABILITY CONCERNS REPORTED
WITH E4
IN PATIENTS HOSPITALIZED WITH MODERATE COVID-19
    * THE CLINICAL PROGRAM INCLUDED CENTERS IN BELGIUM, RUSSIA,
AND
POLAND
    * OVERALL, BLOOD CLOTS WERE INFREQUENT AND WERE SEEN LESS
OFTEN
THAN TYPICALLY REPORTED IN THE LITERATURE FOR PATIENTS WITH
COVID-19

Further company coverage:  MITRA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))